Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Sino Biopharmaceutical ( (HK:1177) ) is now available.
Sino Biopharmaceutical Limited announced the approval of its zongertinib tablets, branded as Hernexeos®, for marketing in mainland China. This drug, developed in collaboration with Boehringer Ingelheim, is the first approved oral HER2 tyrosine kinase inhibitor for treating adult patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2 mutations. The approval is based on positive results from the Beamion-LUNG 1 study, showing high efficacy and a manageable safety profile. This development addresses significant unmet clinical needs in lung cancer treatment in China and enhances the company’s oncology product line.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$9.17 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited is a company incorporated in the Cayman Islands, primarily operating in the pharmaceutical industry. The company, along with its subsidiaries, focuses on developing and promoting pharmaceutical products, with a significant emphasis on oncology treatments.
Average Trading Volume: 185,945,049
Technical Sentiment Signal: Buy
Current Market Cap: HK$138.4B
See more data about 1177 stock on TipRanks’ Stock Analysis page.